Strategic Global Advisors LLC Makes New $1.55 Million Investment in Insulet Corporation $PODD

Strategic Global Advisors LLC acquired a new position in Insulet Corporation (NASDAQ:PODD) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 5,443 shares of the medical instruments supplier’s stock, valued at approximately $1,547,000.

Other hedge funds also recently modified their holdings of the company. Nordea Investment Management AB boosted its stake in Insulet by 35.0% in the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after buying an additional 142,922 shares in the last quarter. Jain Global LLC grew its position in Insulet by 148.2% in the third quarter. Jain Global LLC now owns 106,710 shares of the medical instruments supplier’s stock valued at $32,945,000 after acquiring an additional 63,719 shares during the period. Fisher Asset Management LLC raised its stake in Insulet by 38.1% during the third quarter. Fisher Asset Management LLC now owns 46,273 shares of the medical instruments supplier’s stock worth $14,286,000 after acquiring an additional 12,754 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp raised its stake in Insulet by 26.5% during the fourth quarter. Mitsubishi UFJ Trust & Banking Corp now owns 43,921 shares of the medical instruments supplier’s stock worth $12,484,000 after acquiring an additional 9,206 shares in the last quarter. Finally, Aberdeen Group plc lifted its holdings in shares of Insulet by 45.6% during the fourth quarter. Aberdeen Group plc now owns 225,429 shares of the medical instruments supplier’s stock valued at $64,076,000 after acquiring an additional 70,607 shares during the period.

Insiders Place Their Bets

In other Insulet news, Director Timothy C. Stonesifer purchased 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The stock was purchased at an average cost of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 0.36% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Wells Fargo & Company reduced their target price on shares of Insulet from $360.00 to $255.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Rothschild & Co Redburn restated a “neutral” rating and issued a $220.00 target price (down from $380.00) on shares of Insulet in a research note on Friday, April 24th. Piper Sandler reduced their target price on shares of Insulet from $360.00 to $210.00 in a research note on Wednesday, May 6th. Oppenheimer reduced their target price on shares of Insulet from $300.00 to $210.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Finally, Raymond James Financial set a $216.00 target price on shares of Insulet in a research note on Monday, June 8th. Twenty-one analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $240.78.

Insulet Stock Performance

PODD stock opened at $149.70 on Monday. The business has a fifty day moving average price of $169.92 and a 200 day moving average price of $231.93. Insulet Corporation has a fifty-two week low of $140.63 and a fifty-two week high of $354.88. The stock has a market capitalization of $10.37 billion, a price-to-earnings ratio of 34.81, a P/E/G ratio of 1.18 and a beta of 1.13. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. During the same period last year, the firm posted $1.02 EPS. The business’s revenue was up 33.9% on a year-over-year basis. Insulet has set its FY 2026 guidance at 6.210- EPS. Analysts expect that Insulet Corporation will post 6.46 EPS for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.